Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed in Advanced NSCLC
NCT04856176Phase 2Terminated
- Sponsor
- Tufts Medical Center
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in non-small cell lung cancer (NSCLC), sponsored by Tufts Medical Center. Started Jan 2022; status: terminated.
02
Drugs
sargramostim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04856176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856176.